Mallinckrodt, Endo Merger To Create Pharma Entity Valued At $7 Billion
Mallinckrodt and Endo are merging in a $6.7 billion deal, with a pro forma NYSE listing and $900 million in financing.
Drugmakers Mallinckrodt and Endo to Merge in Nearly $7 Billion Deal
(Reuters) - Mallinckrodt and Endo, drugmakers with a shared history of facing U.S. opioid litigation, have agreed to merge in ...
Drugmakers Mallinckrodt, Endo to Merge, Plan NYSE Listing
Dublin-headquartered Mallinckrodt is taking over smaller rival Endo and planning to list the combined firm on the New York Stock Exchange, the two drugmakers said Thursday.
BioWorld1d
Endo the line: Mallinckrodt merger worth $6.7B
The pairing of Mallinckrodt plc and Endo Inc. is expected to create a pharma heavyweight that will generate $3.6 billion in 2025 revenue after the duo combines their generic pharmaceuticals businesses ...
Mallinckrodt, Endo Merger to Create Diversified Pharmaceuticals Firm
Drugmaker Mallinckrodt struck a deal to buy Endo in an effort to build a diversified pharmaceuticals company with a hefty U.S ...
pharmaphorum2d
Endo files for bankruptcy as it agrees opioid settlement
Endo's slide into bankruptcy follows in the footsteps of Purdue Pharma – which filed in 2019 but is still negotiating opioid settlement and corporate restructuring terms – as well as ...
eLife3d
Brief disruption of activity in a subset of dopaminergic neurons during consolidation impairs long-term memory by fragmenting sleep
Learn more about eLife assessments Sleep disturbances are associated with poor long-term memory (LTM) formation, yet the underlying cell types and neural circuits involved have not been fully decoded.
The EMBO Journal5d
Surface-mediated bacteriophage defense incurs fitness tradeoffs for interbacterial antagonism
Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. Bacteria in polymicrobial habitats are ...